Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in ...

In February, the US Food and Drug Administration (FDA) accepted for priority review ... score Total cumulative OCS dose Time to first use of rescue medication Dupixent (dupilumab) is a fully human ...

March 7 (UPI) --A group of 20 attorneys general filed suit against the Trump administration over its firing of federal workers. Attorneys general from 19 states and Washington sought a court order ...

Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option. A new Phase-3b study has found that ...

NEW YORK (AP) — The Small Business Administration said it will relocate six of its regional offices in so-called “sanctuary cities,” part of a broader Trump administration effort to crack down on ...